Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
Federal push to harness AI in medical research relies on extensive data collection and privacy safeguards.
DLH Holdings Corp (DLHC): Analyzing financial overview and stock performance in the healthcare and technology sectors amidst market volatility.
DLH Holdings secures $23 million contract with NIDA to provide IT services and an informatics system for drug abuse research. ...
Kintara Therapeutics has launched a clinical trial for REM-001, a promising treatment for cutaneous metastatic breast cancer. The trial aims ...
Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
Option Care Health partners with Palantir to optimize operations with AI, joining a list of healthcare organizations leveraging Palantir's AI ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.